These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 29577693)

  • 21. Development of a dual reporter screening assay for distinguishing the inhibition of HIV Tat-mediated transcription from off-target effects.
    Shin Y; Choi BS; Kim KC; Kang C; Kim K; Yoon CH
    J Virol Methods; 2017 Nov; 249():1-9. PubMed ID: 28807730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is there a future for antiviral fusion inhibitors?
    Berkhout B; Eggink D; Sanders RW
    Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of three quantification methods for the TZM-bl pseudovirus assay for screening of anti-HIV-1 agents.
    Xing L; Wang S; Hu Q; Li J; Zeng Y
    J Virol Methods; 2016 Jul; 233():56-61. PubMed ID: 27016178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of Clinical HIV-1 Strains with Resistance to Maraviroc Reveals Strain-Specific Resistance Mutations, Variable Degrees of Resistance, and Minimal Cross-Resistance to Other CCR5 Antagonists.
    Flynn JK; Ellenberg P; Duncan R; Ellett A; Zhou J; Sterjovski J; Cashin K; Borm K; Gray LR; Lewis M; Jubb B; Westby M; Lee B; Lewin SR; Churchill M; Roche M; Gorry PR
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1220-1235. PubMed ID: 28797170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM; Kanmogne GD
    Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
    Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virus.
    Platt EJ; Durnin JP; Kabat D
    J Virol; 2005 Apr; 79(7):4347-56. PubMed ID: 15767435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A sensitive HIV-1 envelope induced fusion assay identifies fusion enhancement of thrombin.
    Cheng DC; Zhong GC; Su JX; Liu YH; Li Y; Wang JY; Hattori T; Ling H; Zhang FM
    Biochem Biophys Res Commun; 2010 Jan; 391(4):1780-4. PubMed ID: 20045672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The V1-V3 region of a brain-derived HIV-1 envelope glycoprotein determines macrophage tropism, low CD4 dependence, increased fusogenicity and altered sensitivity to entry inhibitors.
    Rossi F; Querido B; Nimmagadda M; Cocklin S; Navas-Martín S; Martín-García J
    Retrovirology; 2008 Oct; 5():89. PubMed ID: 18837996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?
    Idemyor V
    HIV Clin Trials; 2005; 6(5):272-7. PubMed ID: 16306033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 tropism for the central nervous system: Brain-derived envelope glycoproteins with lower CD4 dependence and reduced sensitivity to a fusion inhibitor.
    Martín-García J; Cao W; Varela-Rohena A; Plassmeyer ML; González-Scarano F
    Virology; 2006 Mar; 346(1):169-79. PubMed ID: 16309726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P2X1 Receptor Antagonists Inhibit HIV-1 Fusion by Blocking Virus-Coreceptor Interactions.
    Giroud C; Marin M; Hammonds J; Spearman P; Melikyan GB
    J Virol; 2015 Sep; 89(18):9368-82. PubMed ID: 26136569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
    Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
    J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Integrase inhibitor, CCR5 antagonist, fusion inhibitor].
    Gatanaga H
    Nihon Rinsho; 2010 Mar; 68(3):520-4. PubMed ID: 20229801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemokine antagonists as therapeutics: focus on HIV-1.
    Tsibris AM; Kuritzkes DR
    Annu Rev Med; 2007; 58():445-59. PubMed ID: 16958560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of cholesterol and sphingolipids in chemokine receptor function and HIV-1 envelope glycoprotein-mediated fusion.
    Ablan S; Rawat SS; Viard M; Wang JM; Puri A; Blumenthal R
    Virol J; 2006 Dec; 3():104. PubMed ID: 17187670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.